Americans are on track to spend over $1 trillion on prescription drugs this year, with a whopping $132 billion of that going to a single drug class: GLP-1s. But this week, a landmark meta-analysis in The BMJ threw a bucket of cold water on the narrative. After combing through 262 trials with nearly 100,000 participants, researchers found that drugs like tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy) shed serious pounds — but did...